Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Denis Occhipinti
Observed names:
D. Occhipinti,
Denis OCCHIPINTI
Institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic
Observed institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0000-0003-0667-5458
Observed ORCID:
0000-0003-0667-5458
OpenAlex ID:
A5073588803
Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives
2024
·
Sergio Pannunzio
, Armando Di Bello
, et al.
·
Frontiers in Oncology
·
34
PDF
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study
2025
·
Alessandro Inno
, Antonello Veccia
, et al.
·
Cancer Immunology Immunotherapy
·
9
PDF
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer
2024
·
Emanuele Vita
, Federico Monaca
, et al.
·
Cancer
·
8
PDF
Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapy
2026
·
Chiara Ciccarese
, Denis Occhipinti
, et al.
·
Cancer Immunology Immunotherapy
·
4
PDF
Beneficial Effects of Remote Medical Care for Patients with Hereditary Hemorrhagic Telangiectasia during the COVID-19 Pandemic
2021
·
Eleonora Gaetani
, Fabiana Agostini
, et al.
·
Journal of Clinical Medicine
·
4
PDF
Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors
2025
·
Maria Grazia Maratta
, Ileana Sparagna
, et al.
·
Cancers
·
3
PDF
A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study
2025
·
Chiara Ciccarese
, Daniela Arduini
, et al.
·
Tumori Journal
·
2
Safety profile of BCG with or without immunotherapy in non–muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis
2026
·
C. Ciccarese
, D. Occhipinti
, et al.
·
ESMO Open
·
1
Clinical and technical insights on KIM-1: what we need to know
2026
·
Daniela ARDUINI
, Antonio AGOSTINI
, et al.
·
Minerva Urology and Nephrology
·
1
2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma
2024
·
Viria Beccia
, Daniela Arduini
, et al.
·
Expert Review of Anticancer Therapy
·
1
2227P Incidence and patterns of co-occurrence of targetable genomic alterations in metastatic Prostate Cancer (mPC): Implications for personalized treatment stratification
2026
·
D. Arduini
, C. Ciccarese
, et al.
·
Annals of Oncology
Emerging patterns of kidney cancer in young adults: where do we stand?
2026
·
Paola Troisi
, Denis Occhipinti
, et al.
·
Critical Reviews in Oncology/Hematology
Pattern of disease recurrence and outcomes of localized high-risk renal cell carcinoma (RCC) patients treated with adjuvant (adj) immunotherapy: A single center experience.
2026
·
Denis Occhipinti
, Chiara Ciccarese
, et al.
·
Journal of Clinical Oncology
PDF
Incidence and co-occurrence of targetable key genomic alterations (GenAlt) in metastatic prostate cancer (mPC): Preliminary results from the prostate cancer cohort of the FPG500 program.
2026
·
Daniela Arduini
, Chiara Ciccarese
, et al.
·
Journal of Clinical Oncology
PDF
Impact of immunotherapy in patients with upper tract urothelial carcinoma: a meta-analysis of randomized trials
2026
·
Denis Occhipinti
, CHIARA CICCARESE
, et al.
·
SSRN Electronic Journal
PDF
Enhanced response to dabrafenib plus trametinib in a patient with BRAFV600E lung cancer harboring an RNF43 variant of unknown significance: a case report
2025
·
Ettore D’Argento
, Antonio Vitale
, et al.
·
Frontiers in Oncology
PDF
A0655 – Final overall survival of ARIES trial evaluating avelumab monotherapy as first line for patients with advanced urothelial cancer (aUC) unfit for cisplatin and outcome analysis based on baseline characteristics
2025
·
D. Occhipinti
, C. Ciccarese
, et al.
·
European Urology
Final overall survival of ARIES trial evaluating first line avelumab monotherapy for patients with advanced urothelial cancer (aUC) unfit for cisplatin and outcome analysis based on baseline characteristics.
2025
·
Denis Occhipinti
, Chiara Ciccarese
, et al.
·
Journal of Clinical Oncology
Correlation between multiorgan immune-related adverse events and clinical outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) treated with chemo-immunotherapy.
2024
·
Federico Monaca
, Martin Igor Gomez-Randulfe Rodriguez
, et al.
·
Journal of Clinical Oncology
234P Clinical findings and genomic characterization of NRG-1 alterations with a comprehensive genome profiling (CGP) in advanced non-small cell lung cancer (ANSCLC)
2024
·
E. Vita
, L. Mastrantoni
, et al.
·
ESMO Open
Show more works
View as search
Works count:
20
Citation count:
67
H-index:
4
I10-index:
1
Year
Topic
Type